The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial
Open accessAbstract
Importance: Individuals living with schizophrenia are affected by cardiometabolic, endocrine, and motor adverse effects of current antipsychotic medications. Lumateperone is a serotonin, dopamine, and glutamate modulator with the potential to treat schizophrenia with few adverse effects. Objective: To examine the efficacy and safety of lumateperone for the short-term treatment of schizophrenia. Design, Setting, and Participants: This randomized, double-blind, placebo-controlled, phase 3 clinical trial was conducted from November 13, 2014, to July 20, 2015, with data analyses performed from August 13 to September 15, 2015. Patients with schizophrenia who were aged 18 to 60 years and were experiencing an acute exacerbation of psychosis were enrolled from 12 clinical sites in the United States. Interventions: Patients were randomized 1:1:1 (150 patients in each arm) to receive lumateperone tosylate, 60 mg; lumateperone tosylate, 40 mg (equivalent to 42 or 28 mg, respectively, of the active moiety lumateperone); or placebo once daily for 4 weeks. Main Outcomes and Measures: The prespecified primary efficacy end point was mean change from baseline to day 28 in the Positive and Negative Syndrome Scale (PANSS) total score vs placebo. The key secondary efficacy measure was the Clinical Global Impression-Severity of Illness (CGI-S) score. The PANSS subscale scores, social function, safety, and tolerability were also assessed. Results: The study comprised 450 patients (mean [SD] age, 42.4 [10.2] years; 346 [77.1%] male; mean [SD] baseline PANSS score, 89.8 [10.3]; mean [SD] baseline CGI-S score, 4.8 [0.6]). In the prespecified modified intent-to-treat efficacy analysis (n = 435), 42 mg of lumateperone met the primary and key secondary efficacy objectives, demonstrating a statistically significant improvement vs placebo from baseline to day 28 on the PANSS total score (least-squares mean difference [LSMD], -4.2; 95% CI, -7.8 to -0.6; P = .02; effect size [ES], -0.3) and the CGI-S (LSMD, -0.3; 95% CI, -0.5 to -0.1; P = .003; ES, -0.4). For 28 mg of lumateperone, the LSMD from baseline to day 28 was -2.6 (95% CI, -6.2 to 1.1; P = .16; ES, -0.2) on the PANSS total score and -0.2 (95% CI, -0.5 to 0.0; P = .02; ES, -0.3) on the CGI-S. Both lumateperone doses were well tolerated without clinically significant treatment-emergent motor adverse effects or changes in cardiometabolic or endocrine factors vs placebo. Conclusions and Relevance: Lumateperone demonstrated efficacy for improving the symptoms of schizophrenia and had a favorable safety profile. Trial Registration: ClinicalTrials.gov identifier: NCT02282761.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
(1976) · Medical Entomology and Zoology · Cited by 8,899
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa‐Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., et al. (2017) · World Psychiatry · doi:10.1002/wps.20420 · Cited by 1,729
Self-citationHjorthøj, C., Stürup, A. E., McGrath, J. J., & Nordentoft, M. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30078-0 · Cited by 1,304
Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271
Self-citationA depression rating scale for schizophrenics
Addington, D., Addington, J., & Schissel, B. (1990) · Schizophrenia Research · doi:10.1016/0920-9964(90)90005-r · Cited by 1,269
Disability weights for the Global Burden of Disease 2013 study
Salomon, J. A., Haagsma, J. A., Davis, A., de Noordhout, C. M., Polinder, S., Havelaar, A. H., Cassini, A., Devleesschauwer, B., Kretzschmar, M., Speybroeck, N., et al. (2015) · The Lancet Global Health · doi:10.1016/s2214-109x(15)00069-8 · Cited by 1,217
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Self-citationPremature Mortality Among Adults With Schizophrenia in the United States
Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1737 · Cited by 1,083
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Self-citationTherapeutics and Clinical Risk Management
(2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm · Cited by 750
Vancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., Rosenbaum, S., Gaughran, F., Lally, J., & Stubbs, B. (2016) · World Psychiatry · doi:10.1002/wps.20309 · Cited by 659
Self-citationThe Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling.
Overall, J. E., & Gorham, D. R. (1988) · Cited by 586
Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., Samara, M., Rabaioli, M., Bächer, S., Cipriani, A., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16121358 · Cited by 542
Kane, J. M., Kishimoto, T., & Correll, C. U. (2013) · World Psychiatry · doi:10.1002/wps.20060 · Cited by 520
Self-citationSolmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
Self-citationOverall, J. (1988) · Psychopharmacology Bulletin · Cited by 432
Vancampfort, D., Wampers, M., Mitchell, A. J., Correll, C. U., De Herdt, A., Probst, M., & De Hert, M. (2013) · World Psychiatry · doi:10.1002/wps.20069 · Cited by 317
Self-citationFunctional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
Snyder, G. L., Vanover, K. E., Zhu, H., Miller, D. B., O’Callaghan, J. P., Tomesch, J., Li, P., Zhang, Q., Krishnan, V., Hendrick, J. P., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3704-1 · Cited by 289
Self-citationCorrell, C. U. (2010) · European Psychiatry · doi:10.1016/s0924-9338(10)71701-6 · Cited by 273
Self-citationITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
Lieberman, J. A., Davis, R. E., Correll, C. U., Goff, D. C., Kane, J. M., Tamminga, C. A., Mates, S., & Vanover, K. E. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.026 · Cited by 261
Self-citationVanover, K. E., Davis, R. E., Zhou, Y., Ye, W., Brašić, J. R., Gapasin, L., Saillard, J., Weingart, M., Litman, R. E., Mates, S., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0251-1 · Cited by 241
Self-citationDiscussion: recent developments in ascertainment and scaling of the BPRS.
Raskin, A. (1988) · PubMed · Cited by 196
Fleischhacker, W., Galderisi, S., Laszlovszky, I., Szatmári, B., Barabássy, Á., Acsai, K., Szalai, E., Harsányi, J., Earley, W. R., Patel, M., et al. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2019.01.015 · Cited by 149
Patrick, D. L., Burns, T., Morosini, P., Rothman, M. L., Gagnon, D. D., Wild, D. J., & Adriaenssen, I. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802611919 · Cited by 126
General Multistage Gatekeeping Procedures
Dmitrienko, A. A., Tamhane, A. C., & Wiens, B. L. (2008) · Biometrical Journal · doi:10.1002/bimj.200710464 · Cited by 124
Briggs, A., Wild, D., Lees, M., Reaney, M., Dursun, S., Parry, D., & Mukherjee, J. (2008) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-6-105 · Cited by 122
ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
Davis, R. E., & Correll, C. U. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1174577 · Cited by 81
Self-citationKobak, K. A., Leuchter, A. F., DeBrota, D. J., Engelhardt, N., Williams, J. B. W., Cook, I. A., Leon, A. C., & Alpert, J. E. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d20912 · Cited by 67
Harvey, P. D., Khan, A., & Keefe, R. S. E. (2017) · PubMed · Cited by 62
Mixtures of multiple testing procedures for gatekeeping applications in clinical trials
Dmitrienko, A. A., & Tamhane, A. C. (2011) · Statistics in Medicine · doi:10.1002/sim.4008 · Cited by 61
Assessing Positive and Negative Symptoms in Outpatients with Schizophrenia and Mood Disorders
Purnine, D. M., Carey, K. B., Maisto, S. A., & Carey, M. P. (2000) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200010000-00003 · Cited by 45
Wu, C., Wang, S.-C., Yeh, I., et al. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m09898 · Cited by 44
What Are We Looking for in New Antipsychotics?
Correll, C. U. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10075su1.02 · Cited by 34
Self-citationVanover, K. E., Dmitrienko, A. A., Glass, S., Kozauer, S. G., Saillard, J., Weingart, M., Satlin, A., Mates, S. L., Correll, C. U., & Davis, R. E. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby018.831 · Cited by 17
Self-citationCorrell, C. U., Stanford, A. D., Claxton, A., Du, Y., & Weiden, P. J. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.02.021 · Cited by 16
Self-citationKane (2013) · doi:10.1002/wps.v12.3 · Cited by 16
Performance Improvement CME: Long-Term Treatment of Bipolar Disorder
McIntyre, R. S., & Wagner, K. D. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9089pi3cc · Cited by 9
Cited by
Neurobiology of Schizophrenia: A Comprehensive Review
Luvsannyam, E., Jain, M. S., Pormento, M. K. L., Siddiqui, H., Balagtas, A. R. A., Emuze, B. O., & Poprawski, T. (2022) · Cureus · doi:10.7759/cureus.23959 · Cited by 127
Metadata
- Authors
- Correll, C. U., Davis, R. E., Weingart, M., Saillard, J., O’Gorman, C., Kane, J. M., Lieberman, J. A., Tamminga, C. A., Mates, S., & Vanover, K. E.
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2020-04-01
- Volume
- 77
- Issue
- 4
- Pages
- 349
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W3000034835
- Cited by
- 288
- References
- 46
- FWCI
- 35.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.